Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13778589 | 0.92 | L3MBTL1 (0.49) | RXRARXRBMRGPRX4RAB9ASMN1; SMN2 | |
| SCHEMBL9842913 | 0.91 | RXRA (0.49) | RXRARXRBMRGPRX4RAB9ACHRNB2 | |
| SCHEMBL10758358 | 0.88 | MEN1 (0.49) | RAB9ASMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL683554 | 0.84 | RXRA (0.66) | RXRARXRBMRGPRX4RAB9ASMN1; SMN2 | |
| SCHEMBL16594362 | 0.84 | TSHR (0.56) | RAB9ASMN1; SMN2GAAMAPTMAOA | |
| SCHEMBL3764814 | 0.84 | KCNA3 (0.54) | RXRARXRBRAB9AMAPTMEN1 | |
| SCHEMBL5677947 | 0.83 | LMNA (0.62) | RAB9ASMN1; SMN2GAAMAPTMAOA | |
| SCHEMBL29041352 | 0.82 | TSHR (0.65) | RXRARXRBMRGPRX4RAB9AMEN1 | |
| SCHEMBL903883 | 0.82 | TSHR (0.58) | RAB9ASMN1; SMN2GAAMAPTMAOA | |
| SCHEMBL4756260 | 0.81 | MAOB (0.70) | RAB9ASMN1; SMN2GAAMAPTMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | AEGERA THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | AEGERA THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-7253178-B2 | Carboxylic acids | EISAI CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-7253178-B2 | Carboxylic acids | EISAI CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-7253178-B2 | Carboxylic acids | EISAI CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-20040116708-A1 | Insulin sensitizers; antidiabetic agents, antiinflammatory agents; inflammatory bowel disorders | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1375484-A1 | CARBOXYLIC ACIDS | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170845-A1 | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN | SCN1B, SCN3A, SCN1A | RXRA 1433/4885RXRB 1576/4885MRGPRX4 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.